FDA names 15 members for its new Risk Communication Advisory Committee.
The FDA has set up a 15-member Risk Communication Advisory Committee to advise the agency on how best to communicate to the public the risks and benefits of FDA-regulated products. Among these 15 members, encompassing physicians, consumer advocates, and others, is a pharmacy professorBetsy Lynn Sleath, Ph.D., associate professor of pharmaceutical outcomes and policy at the University of North Carolina. The FDA said these 15 members were chosen from among 240 nominations received. The committee, whose formation was recommended by an Institute of Medicine 2006 report, will meet for the first time in the first quarter of 2008.
To see more Daily News articles, click here.
To go to the Drug Topics homepage, click here.
FDA Approves Sulopenem Etzadroxil and Probenecid for Uncomplicated Urinary Tract Infections
October 25th 2024“As the first oral penem approved in the US, Orlynvah offers an excellent alternative treatment option for appropriate patients in the underserved uUTI market,” according to the CEO of Iterum Therapeutics.